Form 4: Entera Bio CFO Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Dana Yaacov-Garbeli, CFO of Entera Bio Ltd., reports the acquisition of stock options and restricted stock units.
Summary
- On April 19, 2024, Dana Yaacov-Garbeli, the Chief Financial Officer of Entera Bio Ltd., acquired 30,151 ordinary shares in the form of restricted stock units and stock options for 130,000 ordinary shares.
- The restricted stock units vest ratably on a quarterly basis over one year, starting April 19, 2024.
- The stock options, with an exercise price of $1.99, vest over three years, with 33% vesting on April 19, 2025, and the remainder vesting ratably on a quarterly basis over the subsequent two years.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a standard practice and generally viewed as a positive incentive for management.
Positives
- The grant of restricted stock units and stock options to the CFO aligns her interests with those of the shareholders.
- The vesting schedules for both the restricted stock units and stock options incentivize long-term performance.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are standard practice in the biotech industry.
- Companies like Amgen, Gilead Sciences, and Biogen commonly use similar equity-based compensation to incentivize their executives.
- The vesting schedules described are typical, with vesting periods ranging from one to four years.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/19/2024 | Date of transaction: Acquisition of restricted stock units and stock options. |
| 04/19/2024 | Vesting commencement date for restricted stock units. |
| 04/19/2025 | First vesting date for 33% of the stock options. |
| 04/19/2034 | Expiration date of the stock options. |
| 04/23/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.